A Randomized, Double Blinded, Positive Controlled Phase Ⅰb Clinical Trial in Participants Aged 2 Months (42-89 Days) and 2 to 5 Years to Evaluate the Safety and Immunogenicity of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

PRO-PCV-1002

A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV13. The trial is a randomized, double blinded, positive controlled study.

2024-01-04

2024-09-02

2025-04-15

Recruiting

Early phase I

140

Inclusion Criteria: 1. Healthy infants aged 2 months (42-89 days); Healthy children aged 2-5 years. 2. Proven vaccination certificate, birth certificate and legal identification documents 3. The participants' guardians can understand and voluntarily sign the informed consent form. 4. Participants and their guardians can obey requirements of the protocol. Exclusion Criteria: 1. Received any pneumococcal vaccine prior to enrollment. 2. History of culture confirmed bacterial pneumonia or invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. 3. History of allergy to the vaccine or vaccine components, including pneumococcal polysaccharide for each serotype, diphtheria CRM197, aluminum phosphate, succinic acid, polysorbate 80 and sodium chloride; or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma. 4. History of dystocia, asphyxia rescue, nervous system damage at birth (only applicable to infants aged 2 months (42-89 days)) 5. Congenital malformations or developmental disorders, genetic defects, severe malnutrition, asthma etc. 6. Autoimmune disease (such as systemic lupus erythematosus) or immunodeficiency/ immunosuppression (such as HIV, organ transplantation) 7. Severe cardiovascular diseases, such as diabetes, liver diseases, kidney diseases, malignant tumors. 8. Family history of mental illness, severe neurological disease (epilepsy or convulsions) or mental illness. 9. History of thyroidectomy, asplenia, functional asplenia; and asplenia or splenectomy resulting from any condition. 10. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets), history of obvious bleeding or bruising after intramuscular injection or venipuncture. 11. Infants 2 months of age (42-89 days) prior to enrollment/children 2 to 5 years of age 6 months prior to enrollment had been treated with corticosteroids, other immunosuppressive agents (excluding corticosteroid spray therapy for allergic rhinitis, superficial corticosteroid therapy for acute non-concurrent dermatitis) or cytotoxic therapy for ≥14 days 12. Infants 2 months of age (42-89 days) prior to enrollment/children 2 to 5 years of age 3 months prior to enrollment received blood products within the past 3 months (excluding hepatitis B immunoglobulin within 1 month). 13. Receipt of other investigational drugs in the past 60 days or have the plan to participate in other clinical trials during this study. 14. Receipt of attenuated live vaccines in the past 14 days. 15. Receipt of inactivated or subunit vaccines in the past 7 days. 16. Acute diseases or acute exacerbation of chronic diseases in the past 7 days. 17. Axillary temperature ≥37.3 °C. 18. According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 140, 'type': 'ESTIMATED'}}

2024-04-30